Mirae Asset Global Investments Co., Ltd. Taysha Gene Therapies, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $24 Billion
- Q4 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 6,829 shares of TSHA stock, worth $11,950. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,829
Previous 7,412
7.87%
Holding current value
$11,950
Previous $14,000
21.43%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TSHA
# of Institutions
121Shares Held
138MCall Options Held
25.9KPut Options Held
24K-
Avoro Capital Advisors LLC New York, NY20MShares$35 Million0.5% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$20.5 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$19 Million0.3% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$15.8 Million1.87% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.91MShares$15.6 Million0.0% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $84.6M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...